Skip directly to content

Publications 2010

2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

TAGline 2010

TAG Applauds World Health Organization Endorsement of Rapid TB Test Which Could Revolutionize Treatment of Tuberculosis
Calls for Further Price Cuts to Ensure Global Access
December 8, 2010 – A new rapid test for tuberculosis (TB) which was just recommended by the World Health Organization (WHO) for widespread use has the potential to revolutionize the world’s fight against the disease, said the Treatment Action Group today, but there are a number of obstacles that threaten to limit its impact, including cost.

Time for a Bold New Vision at the Stop TB Partnership
October 16, 2010 – Tuberculosis—a curable infectious disease—continues to cause illness in more than 9 million people annually. In the past 20 years, the global response to tuberculosis has had moments of vigour. Millions have received treatment for drug-susceptible tuberculosis, treatment of drug-resistant tuberculosis has been integrated into official tuberculosis-control policies worldwide, and there have been major breakthroughs in rapid molecular diagnostics. Nevertheless, almost 2 million people die annually from tuberculosis—most in the prime of their lives—half a million of whom have HIV co-infection, and more than 150 000 have multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis.1

2010 Pipeline Report (Second Edition)
HIV, Tuberculosis, and Viral Hepatitis: Drugs, diagnostics, Vaccines, Immune-based therapies, and Preventive Technologies in Development
September 2010 – This year TAG collaborated with HIV i-Base UK. Simon Collins contributed an in-depth analysis of the Antiretroviral Pipeline and Polly Clayden wrote new chapters for the report on Pediatric Antiretrovirals and HIV diagnostics. The second edition includes information from the XVIII International IAS Conference in Vienna, Austria, July 2010.

Letter to Dr. Fauci to Support HIV and Aging Research
September 20, 2010 – The many complications and comorbidities faced by the aging population of HIV positive people in the United States constitute a rapidly growing medical crisis that has been woefully neglected by U.S. research efforts. According to the Centers for Disease Control, more than half of all HIV-positive Americans will be over the age of 50 by or before the year 2015. Although increasing evidence points to an earlier onset of age related conditions in people living with HIV little is known about pathogenesis, or proper methods to screen for, prevent and manage these conditions, or anticipate the infrastructure needed to deliver care and treatment for people suffering from these conditions.

Mark Harrington at AIDS 2010 from Vienna (Video)
Starting HAART: When to Take the First Step?

July 20, 2010 – Recent guidelines are all recommending that HIV treatment be started at a higher CD4 count because of issues such as the ongoing damage caused by HIV itself, and prevention of transmission. Issues in long-term treatment, such as potential side effects, the development of resistance, the cost and sustainability of programmes in resource-poor settings, are some of the potential problems for such a strategy. This session discussed the pros and cons of early initiation and highlighted areas of controversy and agreement.

Treatment Action Campaign's letter to Ambassador Gips, U.S. Embassy, South Africa
June 17, 2010 – We call on the U.S. government to provide global leadership to achieve millennium development goal (MDG) 6, including universal access to antiretroviral therapy (ART).

TAG Featured in POZ Magazine
April 1, 2010 – Mark Harrington, founding member and executive director of Treatment Action Group (TAG), a giant in the world of HIV/AIDS treatment and advocacy, can boast about many accomplishments: his paradigm-shifting work on the Treatment and Data committee of the AIDS Coalition to Unleash Power (ACT UP), 18 years of continued achievements at TAG, countless scientific articles and speaking engagements, membership on various U.N. advisory committees, even a MacArthur “Genius” grant in 1997.

TB Research Funding Trends, 2005–2008 (Second Edition)
March 2010 – This is an update to Treatment Action Group’s 2009 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through 2008, the last year for which full data are reported. This edition includes updated information about the R&D investments of the Bill & Melinda Gates Foundation, the Research Institute of Tuberculosis, Japan Anti-TB Association (JATA) and the Japanese government.

Issue Brief: A Sound Investment: The Multiplier Effect of AIDS Research
March 2010 – Investments in health research at the National Institutes of Health (NIH) have paid enormous dividends in the health and well-being of people in the U.S. and around the world. HIV and AIDS research supported by NIH has saved and improved the lives of millions and holds great promise for significantly reducing HIV infection rates and providing more effective treatments for those living with HIV/AIDS. Yet years of erratic funding levels for NIH have undermined our nation’s leadership in health research and our scientists’ ability to take advantage of the expand-ing opportunities to advance healthcare. The race to find better treatments and cures for cancer, heart disease, AIDS, and other diseases—and to control global epidemics such as AIDS, tuberculosis, and malaria—depends on robust long-term investment in health research at NIH.

Monitoring TB/HIV Indicators for UNGASS: Kenya, Uganda, and Zambia
January 2010 – Despite being curable, tuberculosis (TB) continues to be the leading cause of death among people with HIV in 2008, accounting for 25% of all HIV-related deaths. The World Health Organization (WHO) has developed a 12-point policy package and recommended collaborative activities to address the TB/HIV coepidemic, encompassing three interventions jointly known as the “Three I’s”: intensified TB case finding (ICF) among people with HIV, TB infection control (IC), and isoniazid preventive therapy (IPT). As part of this strategy, the UNAIDS United Nations General Assembly Special Session on HIV/AIDS (UNGASS) shadow reports that track compliance with the Declaration of Commitment to universal access to HIV are also required to report on the 13 TB/HIV indicators.